244 related articles for article (PubMed ID: 22647432)
1. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
3. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
6. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
7. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
8. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
[TBL] [Abstract][Full Text] [Related]
9. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
10. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats.
Morishima Y; Kamisato C; Honda Y; Furugohri T; Shibano T
Thromb Res; 2013 Jan; 131(1):59-63. PubMed ID: 22999414
[TBL] [Abstract][Full Text] [Related]
11. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban: a new oral direct factor xa inhibitor.
Camm AJ; Bounameaux H
Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]